Fisetin as an adjuvant treatment in prostate cancer patients receiving androgen-deprivation therapy

Future Sci OA. 2022 Feb 11;8(3):FSO784. doi: 10.2144/fsoa-2022-0002. eCollection 2022 Mar.

Authors

Giuseppe Di Lorenzo^{1

2

3}, Luca Scafuri^{1

2}, Ferdinando Costabile^{1

2}, Liuba Pepe³, Anna Scognamiglio³, Felice Crocetto⁴, Germano Guerra³, Carlo Buonerba^{1

2}

Affiliations

¹ Oncology Unit, Hospital 'Andrea Tortora', ASL Salerno, Pagani, Italy.
² Associazione O.R.A., Somma Vesuviana, Naples, Italy.
³ Department of Medicine & Health Science, University of Molise, Campobasso, Italy.
⁴ Department of Neurosciences, Reproductive Sciences & Odontostomatology, Federico II University, Naples, Italy.

No abstract available

Keywords: androgen deprivation therapy; fisetin; prostate cancer.

Publication types

Editorial